Literature DB >> 3028454

Detection of sputum eicosanoids in cystic fibrosis and in normal saliva by bioassay and radioimmunoassay.

J T Zakrzewski, N C Barnes, P J Piper, J F Costello.   

Abstract

We have measured arachidonic acid (AA) metabolites, leukotrienes (LTs) and prostanoids (Ps), in sputum of patients with cystic fibrosis (CF) and in normal saliva using bioassay and radioimmunoassay (RIA). Almost three times as much LTB4 is present in CF extracts compared with slow reacting substances (SRSs). Leukotrienes were not detected in normal saliva. In CF sputum there is a three-fold increase in the level of the vasodilator prostanoid prostaglandin E2 (PGE2) and the stable metabolite of prostacyclin, 6-oxo PGF1 alpha compared with the vasoconstrictor prostaglandin F2 alpha (PGF2 alpha) and thromboxane B2 (TxB2), a hydrolysis product of thromboxane A2. Experiments with BW755c (25 micrograms ml-1, n = 3) indicated that the majority of this activity was not produced during the extraction procedure. The detection of LTs and Ps in sputum of CF patients shows that these substances are present at biologically active concentrations and may contribute to the pathophysiology of this disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3028454      PMCID: PMC1386135          DOI: 10.1111/j.1365-2125.1987.tb03004.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  40 in total

Review 1.  Physiological and pharmacological roles of prostaglandins.

Authors:  P J Kadowitz; P D Joiner; A L Hyman
Journal:  Annu Rev Pharmacol       Date:  1975       Impact factor: 13.820

2.  A chemotactic role for prostaglandins released from polymorphonuclear leucocytes during phagocytosis.

Authors:  G A Higgs; E McCall; L J Youlten
Journal:  Br J Pharmacol       Date:  1975-04       Impact factor: 8.739

3.  Prostaglandin release from human polymorphonuclear leukocytes.

Authors:  R B Zurier
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1976

4.  Macrophages synthesis and release prostaglandins in response to inflammatory stimuli.

Authors:  J L Humes; R J Bonney; L Pelus; M E Dahlgren; S J Sadowski; F A Kuehl; P Davies
Journal:  Nature       Date:  1977-09-08       Impact factor: 49.962

5.  Slow reacting substances: comparison of some properties of human lung SRS-A and two distinct fractions from ionophore-induced rat mononuclear cell SRS.

Authors:  M K Bach; J R Brashler; C D Brooks; A J Neerken
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

6.  Selective inhibitor of slow reacting substance of anaphylaxis.

Authors:  J Augstein; J B Farmer; T B Lee; P Sheard; M L Tattersall
Journal:  Nat New Biol       Date:  1973-10-17

7.  Cystic fibrosis serum promotes [45Ca] uptake by normal human leukocytes.

Authors:  M W Banschbach; A G Karam; P K Love; B C Hilman
Journal:  Biochem Biophys Res Commun       Date:  1978-10-30       Impact factor: 3.575

8.  Degradation of porstaglandin F2alpha in the human pulmonary circulation.

Authors:  P Jose; U Niederhauser; P J Piper; C Robinson; A P Smith
Journal:  Thorax       Date:  1976-12       Impact factor: 9.139

Review 9.  Cystic fibrosis and malnutrition.

Authors:  H P Chase; M A Long; M H Lavin
Journal:  J Pediatr       Date:  1979-09       Impact factor: 4.406

10.  Identification and quantitation of arachidonic-acid metabolic products in rabbit, rat and human saliva.

Authors:  B Rigas; R A Lewis; K F Austen; E J Corey; L Levine
Journal:  Arch Oral Biol       Date:  1983       Impact factor: 2.633

View more
  11 in total

1.  Decreased polymorphonuclear leucocyte chemotactic response to leukotriene B4 in cystic fibrosis.

Authors:  R H Lawrence; T C Sorrelli
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

2.  Leukotriene B4 and asthma.

Authors:  P E Christie; N C Barnes
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

3.  A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.

Authors:  M W Konstan; G Döring; S L Heltshe; L C Lands; K A Hilliard; P Koker; S Bhattacharya; A Staab; A Hamilton
Journal:  J Cyst Fibros       Date:  2014-01-17       Impact factor: 5.482

Review 4.  Pyocyanin effects on respiratory epithelium: relevance in Pseudomonas aeruginosa airway infections.

Authors:  Balázs Rada; Thomas L Leto
Journal:  Trends Microbiol       Date:  2012-11-07       Impact factor: 17.079

5.  Prospective study of mycobacterial infections in patients with cystic fibrosis.

Authors:  L Hjelte; B Petrini; G Källenius; B Strandvik
Journal:  Thorax       Date:  1990-05       Impact factor: 9.139

6.  Eicosanoid mediator expression in mononuclear and polymorphonuclear cells in normal subjects and patients with atopic asthma and cystic fibrosis.

Authors:  L M Kuitert; R Newton; N C Barnes; I M Adcock; P J Barnes
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

7.  Cif is negatively regulated by the TetR family repressor CifR.

Authors:  Daniel P MacEachran; Bruce A Stanton; George A O'Toole
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

8.  Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients.

Authors:  Jun Yang; Jason P Eiserich; Carroll E Cross; Brian M Morrissey; Bruce D Hammock
Journal:  Free Radic Biol Med       Date:  2012-05-08       Impact factor: 7.376

9.  Role of elevated plasma soluble ICAM-1 and bronchial lavage fluid IL-8 levels as markers of chronic lung disease in premature infants.

Authors:  S Little; T Dean; S Bevin; M Hall; M Ashton; M Church; J Warner; J Shute
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

10.  Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes.

Authors:  Veerle Reynders; Stefan Loitsch; Constanze Steinhauer; Thomas Wagner; Dieter Steinhilber; Joachim Bargon
Journal:  Respir Res       Date:  2006-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.